highlight
- DJS antibody – An investee company acquired by AbbVie. $255 million Cash at closing and potential future milestones focused on novel antibodies against difficult-to-drug protein targets in immunology and beyond
- Ducentis BioTherapeutics – Arcutis Biotherapeutics Brings Portfolio Companies to Largest $400 millionincluding prepaid cash for $16 million and Arcutis shares at approximately $14 millionRecognizing Its Scientific Transformational Potential and Leading Preclinical Assets in the Development of Atopic Dermatitis
- RQ Biotechnology – Portfolio companies co-founded include AstraZeneca and $157 million Plus royalties for MAbs that prevent COVID-19 in vulnerable patients
- surgery hero – Investment in the world’s first digital coaching service for patients preparing for surgery.Revenue to help expand the solution in the UK and accelerate its launch in the US
- OBN Award – RQ Bio named Most Impactful UK Deal 2022 and LifeArc named Most Impactful Business Support Organization
London, February 1, 2023 /PRNewswire/ — LifeArc Ventures, committed to investing in innovative early-stage life sciences companies, today provides a portfolio update.
Claire Tarlowhead of LifeArc Ventures, said: “Our team has had a very busy and productive year, with two major exits, exciting advancements in our portfolio and new investments expanding our healthtech portfolio. New investments in translational science. We look forward to continuing to identify opportunities.
“We take pride in the hands-on support we provide to our portfolio companies, providing strategic, practical and scientific guidance and funding. Demonstrating continued global interest in science and continued opportunity, LifeArc Ventures also played a key role in the landmark AstraZeneca COVID-19 antibody licensing agreement with RQ Bio. , lab access, and antibody expertise.”
First MAb discovered by RQ Bio less than 12 months after discovery with the initiation of AstraZeneca’s SUPERNOVA Phase I/III trial of AZD5156 (combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of COVID-19 I entered a clinical trial. AstraZeneca licensed his AZD3152 from RQ Bio. May 2022.
Hugo FryCEO of RQ Biotechnology commented: “LifeArc had a vision from the beginning to co-found and support RQ Bio. As a result, new and innovative antibodies have been discovered that may protect vulnerable patients from Covid. In addition, companies have emerged to develop medicines for immediate and long-term protection for vulnerable people at risk of severe illness and death from many viral infections. LifeArc is a major shareholder and scientific partner and will continue to support and collaborate with RQ Bio to ensure the company’s innovations have the greatest impact on public health, medicine and patients. “
Our rapidly growing portfolio includes 14 companies, with a goal of adding at least three new investments each year. The recent addition of Surgery Hero has expanded into HealthTech. We were inspired by their vision to reduce the burden on an overwhelmed healthcare system while significantly improving the clinical outcomes and experience of patients undergoing surgery.
Doctor Robbie HuddlestonCMO and Co-Founder, Surgery Hero added: “We are extremely grateful for the trust LifeArc has shown us as an investor and for the support they have provided over the years.The team has extensive experience in the healthcare sector and has been a valuable resource. He will provide guidance in shaping and defining the company’s strategy at this critical stage of growth.”
Concluding a Successful Year, Proud to Recognize RQ Bio’s AstraZeneca Deal Named Most Influential UK Deal at OBN Awards and LifeArc Most Influential Business Support Organization think. We believe LifeArc’s awards are a recognition of the unique combination of skills and expertise that LifeArc and LifeArc Ventures provide to support and advance life-changing science.
LifeArc Ventures launches a new look and feel. You can now follow us on our dedicated LinkedIn page and Twitter, as well as on our upcoming new LifeArc Ventures website. We also regularly publish podcasts featuring interviews with portfolio companies, industry leaders, scientists, and investors. will be hosted on
We have many other exciting investments underway and we will hear more in the coming year. We are focused on being a capable co-investor and partner in leading and co-investing early-stage life sciences companies. We are always on the lookout for inspiring, science-driven companies and talented teams who can benefit from our translational advice, scientific expertise and funding. We are open to new opportunities and welcome referrals, so please contact us if you think we can help.
Stay up to date on news and activities by visiting our new LinkedIn and Twitter @LifeArcVentures.
contact address:
life arc [email protected]
Claire Tarlow
MOPR Advisory
Mo Noonan / Jonathan Bart Phone: +44 (0) 7876 444977 / 07860 361746
About LifeArc
LifeArc is a self-funded medical research charity that has more than 25 years of experience translating early science into healthcare treatments, including the diagnosis of antibiotic resistance and four licensed medicines. Our model is built on collaboration, investing in seed and Series A stage companies through the LifeArc Ventures team, with significant additional investments reserved for successful portfolio companies. Our venture approach focuses on investing in new translational science and technology with the dual goals of generating financial benefits for charities and positive patient impact.
For more information, visit www.lifearc.org or follow us on LinkedIn or Twitter (@LifeArcVentures).
Logo – https://mma.prnewswire.com/media/1993881/LifeArc_Logo.jpg
SOURCE life arc
